SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001829126-23-006199
Filing Date
2023-09-19
Accepted
2023-09-19 16:41:40
Documents
15
Period of Report
2023-09-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8ka.htm   iXBRL 8-K/A 58442
2 EXHIBIT 4.1 titanpharma_ex4-1.htm EX-4.1 106896
3 EXHIBIT 10.1 titanpharma_ex10-1.htm EX-10.1 270647
4 EXHIBIT 10.2 titanpharma_ex10-2.htm EX-10.2 89917
  Complete submission text file 0001829126-23-006199.txt   803688

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ttnp-20230913.xsd EX-101.SCH 3021
6 XBRL LABEL FILE ttnp-20230913_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE ttnp-20230913_pre.xml EX-101.PRE 22363
9 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8ka_htm.xml XML 3814
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-13341 | Film No.: 231264337
SIC: 2836 Biological Products, (No Diagnostic Substances)